AI brief of an SEC Form 8-K · Charles River Laboratories (CRL)

Charles River Q1 revenue rose 1.2% to $995.8 million; GAAP loss of $0.30 per share

Mixed Impact 3 of 5 earnings Written later

Charles River reported first-quarter 2026 revenue of $995.8 million, up 1.2% from a year earlier but down 1.5% on an organic basis. The GAAP net loss was $14.8 million, or $0.30 per diluted share, mainly due to a $118.0 million loss on assets held for sale tied to the CDMO and Cell Solutions divestiture, which closed May 6, 2026. Non-GAAP EPS was $2.06, down 12.0%, and the company reaffirmed its 2026 organic revenue and non-GAAP EPS guidance while lowering its reported revenue outlook by about 50 basis points.

Key points

  • Revenue was $995.8 million, up 1.2%; organic revenue declined 1.5%.
  • GAAP net loss of $14.8 million, or $0.30 per diluted share, versus net income of $25.5 million, or $0.50, in Q1 2025.
  • Non-GAAP diluted EPS was $2.06, down 12.0% from $2.34 a year earlier.
  • 2026 non-GAAP EPS guidance of $10.80 to $11.30 was reaffirmed; reported revenue outlook was cut by about 50 basis points on foreign exchange assumptions.

The filing

CompanyCharles River Laboratories (CRL)
Form8-K, current report
Filed with the SECMay 7, 2026, 7:14 AM ET
Accession number0001100682-26-000036

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.